|
Raising the bar for lower-risk myelodysplastic syndromes |
Apr 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
Apr 2023 |
American Journal of Hematology |
Aplastic Anemia |
|
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes |
Apr 2023 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia |
Mar 2023 |
International Journal of Hematology |
Aplastic Anemia |
|
T cell dysfunctions in myelodysplastic syndromes |
Jan 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Allogeneic bone marrow transplantation for aplastic anemia |
Dec 2022 |
International Journal of Hematology |
Aplastic Anemia |
|
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
Apr 2021 |
Haematologica |
Aplastic Anemia |
|
Palliative Medicine in Myelodysplastic Syndromes: Patients and Caregivers - A Qualitative Study |
Apr 2021 |
BMJ Supportive & Palliative Care |
Myelodysplastic Syndromes (MDS) |
|
Eltrombopag in children with severe aplastic anemia |
Apr 2021 |
Pediatric Blood & Cancer |
Aplastic Anemia, Pediatric |
|
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
Apr 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
